Most Recent Update on Price Move: IRadimed Corporation (NASDAQ: IRMD)

On Monday, IRadimed Corporation (NASDAQ: IRMD) shares price traded between $24.90 and $26.14 during the last trading session above/below with +2.54% at $25.00. The shares recorded a trading volume 72,761 shares as compared to its average volume of 76,810 shares. Over the one year trading period, the stock has a peak price of $38.78 and its down is recorded at $13.06.

CORPORATION (IRMD) recently reported financial results for the three months and year ended December 31, 2018.

Financial Results

For the fourth quarter ended December 31, 2018, the Company stated revenue of $8.3M contrast to $6.7M for the fourth quarter 2017. Net income was $1.7M, or $0.14 per diluted share, contrast to net income of $0.2M, or $0.02 per diluted share for the fourth quarter 2017. Net income for the three months ended December 31, 2017 includes a one-time charge of $0.5M related to the Tax Cuts and Jobs Act (“TCJA”). Gross profit margin was 76.2 percent, contrast to 75.5 percent for the fourth quarter 2017. Domestic sales were 80.8 percent of total revenue, contrast to 79.4 percent for the fourth quarter 2017. Revenue from sales of our 3880 MRI compatible patient vital reaches into monitoring system was $2.1M for the fourth quarter 2018 contrast to $0.9M for the fourth quarter 2017.

Non-GAAP net income was $2.0M for the quarter ended December 31, 2018, which excludes $0.3M of stock compensation expense, net of tax. Non-GAAP net income for the quarter ended December 31, 2017 was $1.1M, which excludes $0.5M of stock compensation expense, net of tax and a one-time charge of $0.5M resulting from the TCJA. Non-GAAP earnings per diluted share was $0.16, contrast to $0.10 for the fourth quarter 2017. Free cash flow was $3.5M, contrast to $1.3M for the fourth quarter 2017.

“Revenue for the fourth quarter exceeded our expectations and raised over 24% from the fourth quarter last year. On an yearly basis, revenue raised 32%, with the strongest growth coming from sales of our patient vital reaches into monitoring systems. Earnings also exceeded our expectations and is Because of the collective efforts of everyone at IRADIMED. I am very happy with these results and the Company’s performance this year. As I look forward to 2019, I expect to continue to build on this strong performance,” stated Roger Susi, President and Chief Executive Officer of the Company.

Financial Guidance

This financial guidance includes the predictable impact of our CE Mark expiration as reported on January 22, 2019.

For the full year 2019, the Company expects to report revenue of $38.5M to $39.5M, GAAP diluted earnings per share of $0.60 to $0.64 and non-GAAP diluted earnings per share of $0.69 to $0.73.

For the first quarter 2019, the Company expects to report revenue of $8.3M to $8.5M, GAAP diluted earnings per share of $0.10 to $0.11 and non-GAAP diluted earnings per share of $0.12 to $0.13.

The Company’s non-GAAP earnings per share guidance excludes stock-based compensation expense, net of tax, which the Company expects to be about $1.2M for the year ending December 31, 2019. For the first quarter 2019, the Company’s non-GAAP earnings per share guidance excludes stock-based compensation expense, net of tax of $0.3M.

(IRMD) price volatility for a month noted as 3.96% however its price volatility for a week documented as 3.63%. The corporation holds 10.89 million outstanding shares and its 4.90 million shares were floated in the market. The stock established a negative trend of -3.51% in last week and indicated fall of -9.84% in previous month.

 

 

Leave a Reply

Your email address will not be published. Required fields are marked *